AbbVie Inc. Is Closer to Much-Needed Diversification, but Is It Enough? Motley Fool Other drugs like Elagolix and daclizumab also address meaningful potential markets, and AbbVie isn't known for moving low-probability drugs into expensive late-stage tests. Even so, there are "buts" here – the success of Elagolix and daclizumab will ... |
